RayzeBio's stock has fallen near its original IPO price, presenting an attractive buying opportunity. RYZB's lead drug in Phase-3 clinical testing has best-in-class potential for the treatment of ...

Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward ...

RayzeBio is a recent IPO and a late-stage developer of radiotherapeutic product candidates targeting various cancers. Find out my analysis of RYZB stock.

Radiopharmaceutical drugmaker RayzeBio drew interest from two other large drugmakers before agreeing to a $4.1 billion buyout by Bristol Myers Squibb, newly published documents show.

Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that t ...

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that t ...

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

Shares in RayzeBio (NASDAQ:RYZB) doubled after Bristol Myers Squibb (NYSE:BMY) said it will buy it for about $4.1 billion. Bristol Myers is paying $62.50 per share for the cancer drug maker, which ...